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OBJECTIVE: To perform a molecular characterization of the C1q, C2 and C4 genes in patients with juvenile
systemic lupus erythematosus.
METHODS: Patient 1 (P1) had undetectable C1q, patient 2 (P2) and patient 3 (P3) had decreased C2 and patient
4 (P4) had decreased C4 levels. All exons and non-coding regions of the C1q and C2 genes were sequenced.
Mononuclear cells were cultured and stimulated with interferon gamma to evaluate C1q, C2 and C4 mRNA
expression by quantitative real-time polymerase chain reaction.
RESULTS: C1q sequencing revealed heterozygous silent mutations in the A (c.276 A.G Gly) and C (c.126 C.T
Pro) chains, as well as a homozygous single-base change in the 39 non-coding region of the B chain (c*78 A.G).
C1qA mRNA expression without interferon was decreased compared with that of healthy controls (p,0.05) and
was decreased after stimulation compared with that of non-treated cells. C1qB mRNA expression was decreased
compared with that of controls and did not change with stimulation. C1qC mRNA expression was increased
compared with that of controls and was even higher after stimulation. P2 and P3 had Type I C2 deficiency
(heterozygous 28 bp deletion at exon 6). The C2 mRNA expression in P3 was 23 times lower compared with that
of controls and did not change after stimulation. The C4B mRNA expression of P4 was decreased compared with
that of controls and increased after stimulation.
CONCLUSIONS: Silent mutations and single-base changes in the 39 non-coding regions may modify mRNA
transcription and C1q production. Type I C2 deficiency should be evaluated in JSLE patients with decreased C2
serum levels. Further studies are needed to clarify the role of decreased C4B mRNA expression in JSLE
pathogenesis.
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& INTRODUCTION
Inherited deficiencies of the complement components
C1q, C2 and C4 are frequently associated with the
development of systemic lupus erythematosus (SLE) due
to the impaired clearance of apoptotic debris, a decreased
capacity for immune-complex handling, and/or their role in
peripheral B-cell tolerance (1-9).
Homozygous C1q deficiency is the strongest genetic risk
factor related to SLE (3,10-12). Similarly, both Type I and II
C2 deficiency have been associated with SLE (4,13-17). In
addition, homozygous C4A deficiency is approximately 10
times more frequent in patients with SLE (4,18-22).
Few studies have evaluated the non-coding regions and
mRNA expression of complement genes. Furthermore,
complement deficiencies are rare among SLE patients but
are common among patients with juvenile SLE (JSLE) (23).
We previously showed an underlying primary complement
deficiency in seven JSLE patients (3). We had access to DNA
samples and/or peripheral cells from four of these patients,
and to better understand these inherited deficiencies, we
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Table 1 - Complement component values from four juvenile systemic lupus erythematosus patients selected for
molecular characterization from a cohort of seven patients previously determined to have primary complement
deficiencies.
Patient C1q (33-209 mg/l) C2 (14-25 mg/l) C3 (0.5-1.8 g/l) C4 (0.1-0.4 g/l) C4 copy number
P1 0.0/0.0 (anti-C1q -) 8.7 0.87 0.13 Not done
P2 135.6 4.1/0.0 1.02 0.0/0.08 2 copies C4A 1 copy C4B
P3 4.6/12 (anti-C1q +) 3.4/14 1.11 0.14 Not done
P4 38.7 14.6 0.76 0.04/0.05 2 copies C4A 3 copies C4B
*There was neither patient with C1r or C1s alterations, nor with persistent low C3 levels.
Table 2 - Clinical and laboratory findings from four juvenile systemic lupus erythematosus patients with primary
complement deficiencies who were selected for molecular characterization (3).
Patient/complement
deficiency Gender
Age at diagnosis
(years) Clinical and laboratory findings/Evolution
P1/C1q female 6 Photosensitivity, membranous glomerulonephritis, positive ANA, anti-dsDNA, anti-
Sm, anti-RNP and anti-La/lost for follow-up
P2/C2 female 13 Diffuse proliferaitive glomerulonephritis, thrombocytopenia, positive ANA, anti-Ro,
and anti-La. A brother with SLE and mother with Sjo¨gren’s syndrome/dead
P3/C2 female 6 Serositis, arthritis, lymphopenia, photosensitivity, alopecia, oral ulcers, positive ANA
and anti-dsDNA/follow-up
P4/C4 female 6 Arthritis, serositis, seizures, hemolytic anemia, lymphopenia, positive ANA and anti-
dsDNA/follow-up
Figure 1 - C1qA gene sequencing from juvenile systemic lupus erythematosus patient 1 (P1) and P1’s mother. A – Nucleotide sequence
alignment for P1 and P1’s mother; B – Amino acid sequence for P1 and P1’s mother; C and D – Nucleotide chromatograms of P1 and P1’s
mother, respectively. NG_007282.1 is the reference codified sequence for C1qA. The arrows indicate the variation sites (exon 3, c.276
A.G Gly; c.295 A.C Ile-Leu).
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conducted a molecular characterization of the C1q, C2 and C4
genes.
& MATERIALS AND METHODS
Among 72 JSLE patients, 16 had primary immunodefi-
ciency, and seven of the 16 were determined to have
complement deficiency based on a combination of low or
undetectable serum levels of C1q, or C1s, C1r, C2, C3 or C4
with normal levels of the other components in at least two
samples and low activity/inactive disease (SLEDAI-2K
score,4) (3). Therefore, we selected four patients: patient
1 (P1) had undetectable serum C1q, normal C3 and C4
levels, negative anti-C1q and available DNA and mono-
nuclear cells; patient 2 (P2) had decreased IgA, C2 and C4
serum levels and stored DNA but no cells available for
culture; patient 3 (P3) had decreased C2 and normal C3 and
C4 levels; and patient 4 (P4) had repeated decreased C4 and
normal C1q, C2 and C3 levels and peripheral cells available
for culture (Tables 1 and 2). Three healthy controls matched
by age and gender and with normal complement levels were
also enrolled. Patients fulfilled the revised American College
of Rheumatology classification criteria, and informed consent
was obtained for all participants after the local ethics
committee had approved the study (24,25).
We previously determined the C4 gene copy number by
quantitative real-time polymerase chain reaction (qRT-
PCR), as reported (3,26) (Table 1).
All exons and 39 and 59 non-coding regions (UTR) of the
C1q and C2 genes (3 exons each for the C1q A, B, and C
chains and 18 exons for the C2 gene) were sequenced.
Primers (Supplementary Table) were designed using the
reference sequences deposited in GenBank (NG_007282.1
for C1qA, NG_007283.1 for C1qB, NG_007565.1 for C1qC
and NG_011730.1 for C2) with the Primer-BLAST program.
DNA was obtained using the QIAamp DNA Blood Midi kit
(N˚ 51104 Qiagen, Hilden, Germany), and purity and
concentration were determined with a NanovueH spectro-
photometer (GE Healthcare, USA). Each PCR reaction was
performed in a final volume of 25 ml containing 100 ng of
DNA, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.0 mM
MgSO4, 100 mM each of dATP, dCTP, dGTP and dTTP,
0.5 mM of each primer and 1.5 U of High-Fidelity Platinum
Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA). The
amplification conditions included 35 cycles of 95 C˚ for 30 s,
60 C˚ for 30 s and 72 C˚ for 2 min, with an initial denaturing
step of 95 C˚ for 5 min and a final extension step of 72 C˚ for
7 min. Products were purified using the GFX PCR DNA and
Gel Band Purification Kit (GE Healthcare Life Science, UK).
Amplicons and primers were sent to Centro de Estudos do
Genoma Humano for sequencing. The BioEdit and ClustalW
sequence alignment editors (http://www.mbio.ncsu.edu/
bioedit/bioedit.html) were used to align the nucleotide
sequences. The BLAST program (http://blast.ncbi.nlm.nih.-
gov/Blast.cgi) was used to search variant sequences obtained
from the human genomic database. The Chromas software
program was used for chromatogram visualization. Type I
C2 deficiency was evaluated by PCR as previously described
and confirmed by gene sequencing (3,27).
The quantitative analysis of C1q, C2 and C4 mRNA was
performed using peripheral mononuclear cells obtained by
centrifugation using Ficoll-Paque Plus (GE Healthcare,
Piscataway, NJ, USA) and cultured in supplemented DMEM
medium (10% fetal bovine serum, 10,000 U/ml penicillin and
100 g/ml streptomycin) at 37 C˚ with 5% CO2 for 36 hours.
Figure 2 - C1qB gene sequencing from juvenile systemic lupus erythematosus patient 1 (P1) and P1’s mother. A – Nucleotide sequence
alignment for P1 and P1’s mother; B and C – Nucleotide chromatograms of P1 and P1’s mother, respectively. NG_007283.1 is the
reference codified or mRNA sequence for C1qB. The arrow indicates the variation site (39 UTR c*78 A.G).
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Parallel cultures were stimulated with 100 U/ml of recombi-
nant human interferon gamma (IFNc; N˚ 300-02 Preprotech,
Rocky Hill, NJ, USA) as previously described (28). RNA was
obtained from cultures using an RNeasy Midi Kit (N˚ 74104,
Qiagen, Hilden, Germany). RNA (500 ng) was reverse-
transcribed to produce complementary DNA (cDNA) using
the SuperScript III First-Strand Synthesis System for RT-PCR
(N˚ 18080-051, Invitrogen, Carlsbad, CA, USA). The qRT-PCR
was performed using 2 ml of cDNA, 1 mM each of forward
and reverse primers and 1X SYBR Green Mix QuantiFast PCR
Kit (N˚ 204054, Qiagen, Hilden, Germany) in a StepOnePlus
Real-Time PCR System (Applied Biosystems, Forrest City,
CA, USA). The cycling parameters included an initial 15 min
hot start at 95 C˚, followed by 50 cycles of 15 s at 95 C˚ and 30 s
at 60 C˚. C4B primers were designed based on a GenBank
reference sequence (NG_011638, Supplementary Table).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an endogenous reference gene for qRT-PCR reaction
normalization. Relative expression (RE) was determined by
the standard curve method, and mean values are presented
here as relative variation expression (RVE) obtained from
RVE = target gene RE – GAPDH RE.
A t-test was used to compare the control and untreated
samples and the patient treated and untreated samples.
p,0.05 was considered significant.
& RESULTS
C1q gene sequencing (P1) revealed a heterozygous silent
mutation in exon 3 of the A chain (c.276 A.G Gly), a
homozygous single-base change in the 39 UTR of the B chain
(c*78 A.G), and a heterozygous silent mutation in exon 2 of
the C chain (c.126 C.T Pro) (Figures 1,2,3). The qRT-PCR
analysis revealed that C1qA mRNA expression was
decreased compared with that of healthy controls (p,0.05)
and was also decreased after IFNc stimulation (treated cells)
compared with that of non-treated cells; C1qB mRNA
expression was decreased compared with that of controls
and did not change with stimulation, and C1qC mRNA
expression was increased compared with that of controls
and was even higher after IFNc stimulation (Figure 5A).
P1’s healthy mother had an identical but homozygous
silent mutation in the A chain, a homozygous single-base
Figure 3 - C1qC gene sequencing from juvenile systemic lupus erythematosus patient 1 (P1) and P1’s mother. A – Nucleotide sequence
alignment for P1 and P1’s mother; B and C – Nucleotide chromatograms of P1 and P1’s mother, respectively. NG_007565.1 is the
reference codified sequence for C1qC. The arrow indicates the variation site (exon 2, c.126 C.T Pro).
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change in the B chain, a heterozygous silent mutation in the
C chain, and an additional missense mutation in the A chain
(c. 295 A.C Ile-Leu) (Figure 1). The peripheral cells of the
mother were not available for mRNA expression.
P2 and P3 had a heterozygous 28 bp deletion at exon 6,
characterizing Type I C2 deficiency, as shown in Figure 4.
The C2 mRNA expression (P3) was 23 times lower
compared with that of controls and did not change after
IFNc stimulation (Figure 5B).
The C4B mRNA expression in P4 was significantly
decreased compared with that of controls and increased
after IFNc stimulation (Figure 5C). The C4A mRNA
expression was not technically adequate, and it was there-
fore not considered for analysis.
& DISCUSSION
For the first time in JSLE patients, we showed hetero-
zygous silent mutations, a homozygous single-base change
in the 39 UTR and decreased mRNA expression for the C1q
gene; a heterozygous Type I deficiency and decreased
mRNA expression for the C2 gene; and decreased mRNA
expression for the C4B gene.
Figure 4 - Type I C2 deficiency in juvenile systemic lupus erythematosus patients 2 (P2) and 3 (P3). A – Nucleotide sequence alignment
for P2 and P3; B and C – Nucleotide chromatograms for P2 and P3, respectively. NG_11730.1 is the reference DNA sequence for C2, and
NG_11730 is the codified sequence for C2 (final region of exon 6). The blue arrow indicates the last nucleotide of exon 6, and the red
arrow indicates the initial deletion site; D – Agarose gel electrophoresis showing the heterozygous 28 bp deletion in exon 6 of the C2
gene. Lane 1: 100 bp DNA ladder; lane 2: P2; lane 3: P3; lane 4: positive control; lane 5: negative control. The blue and red arrows
indicate the 174 bp and 146 bp fragments, respectively.
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Although complement deficiencies were the first identi-
fied genetic risk factors for SLE, it remains unclear how
these deficiencies should be assessed (2-4,7,8,27,29).
Studies have described nonsense and missense mutations
in the C1q gene, with a total of 12 causative mutations
(3-5,10-12,23,30-37). Single nucleotide polymorphisms and
silent mutations have also been described (12,38). However,
although there were no amino acid changes due to the
identified base changes, the mRNA expression of the C1qA,
B and C chains was altered. There is evidence that silent
mutations can influence gene expression via alternative
splicing by altering the exonic splicing enhancer or silencer
sites (39). There is no evidence that heterozygous mutations
of the C1q gene can lead to lupus if the other allele is normal.
Of note, our patient presented photosensitivity, which is a
characteristic associated with a single-nucleotide change in
the C1qA gene (38). In addition, Rafiq reported allelic
variance in the 39UTR of the C1qB chain associated with low
C1q serum levels (36). The fact that the 39 UTR single-base
change in C1qB was homozygous implies that the mother
and father each have one allele with the same sequence
variants. P1’s mother had normal C1q levels and did not
present any symptoms of autoimmune disease; however, she
harbored silent mutations with an additional missense
mutation in the A chain. Because the C1q protein was
present in P1’s mother, it becomes questionable whether the
observed variants are, by themselves, pathogenic (40,41).
Peripheral cells from the patient’s father and mother were
not available for mRNA expression analysis, which could
have addressed on the latter speculation.
An intriguing aspect of these results was the observation
of mRNA expression from the C1q chains after IFNc
stimulation. IFNc is able to induce and up-regulate
complement production by monocytes (28,42,43). C1qA
and B expression was decreased, and C1qC was increased,
which suggests deregulated production that could influence
the heterotrimeric assembly of protein. Nanjou et al.
demonstrated that only one defect in any C1q chain can
compromise the entire synthesis and secretion of the C1q
protein (37). Because mRNA was still expressed, it is
unlikely that the observed base changes could completely
block protein expression, and alternative causes must be
considered. Therefore, further work assessing mRNA
stability and translation efficiency will be needed.
Type I C2 deficiency is due to a 9 bp deletion from the 39
end of exon 6 and a 19 bp deletion from the 59 region of the
following intron, leading to a frame shift and a premature
stop codon (2,13,15,16,29). More than half of individuals
with primary C2 deficiency develop SLE or lupus-like
disease (2,29). C2 gene sequencing was performed because
most Type I deficiencies associated with SLE are homo-
zygous and because Zhu et al. have reported a compound
heterozygous Type I and II C2 deficiency in an African-
American family (14-16,29).
Although the Type I C2 deficiency was heterozygous, it
resulted in a 23-fold reduction in mRNA expression. Lipsker
et al. observed decreased but still detectable C2 levels in SLE
patients with a heterozygous Type I C2 deficiency (43). Our
findings raise both (1) the possibility that heterozygous C2
mutations alone or in combination with other factors could
lead to SLE and (2) the question of why C2 mRNA
expression was so low when the patient still had one
functional C2 gene. Therefore, further JSLE patients with
decreased C2 serum levels should be evaluated for Type I
C2 deficiency to better understand the relationship of this
condition with the disease.
The C4A and C4B genes each have 41 exons and differ
from each other by only five nucleotides. The number of
gene copies ranges from two to eight, and deficiencies in
these two genes have been associated with SLE (18-
20,44,45). P4 had persistently low C4 serum levels, with
two copies of C4A and three of C4B; the C4B mRNA
expression in this individual was significantly decreased
compared with controls and increased after IFNc stimula-
tion. Although this was an interesting finding, attributing
the abnormal C4B mRNA expression to a gene mutation
requires presuming that there were mutations in most or all
of her three copies, which is possible but unlikely.
Additionally, we would presume that there was a simulta-
neous problem with C4A transcription, which could not be
evaluated. Thus, further work is needed to clarify the role of
decreased C4B mRNA expression in JSLE pathogenesis.
Figure 5 - Relative expression of mRNA in cells from juvenile
systemic lupus erythematosus patients and controls and after in
vitro IFN-c stimulation (treated). A – The relative expression of
the C1q A, B and C chains in P1’s cells; B – The relative expression
of C2 in P3’s cells; C – The relative expression of C4B in P4’s cells.
RVE – relative variation expression. *indicates a significant
difference, p,0.05.
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This study was unprecedented because it involved the
sequencing of all exons and non-coding regions of the C1q
and C2 genes as well as the evaluation of mRNA expression.
The limitations included the small number of patients,
which created the need for experimental replicates, and the
need for fresh mononuclear cells for mRNA expression
analysis.
In conclusion, silent mutations and single-base changes in
the 39 non-coding region may modulate mRNA transcrip-
tion and C1q production; Type I C2 deficiency should be
evaluated in JSLE patients with decreased C2 serum levels;
and further studies are needed to clarify the role of
decreased C4B mRNA expression in JSLE pathogenesis.
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